JavierEOesterheldMD

Pediatric Hematology & Oncology • Charlotte, NC

Jeff Gordon Children’s Foundation Endowed Chair Cancer and Blood Disorders @ Levine Children’s Specialty Medical Director, Pediatric Hematology/Oncology/BMT and Palliative Care; Levine Children's Hospital

Join to view full profile

Dr. Oesterheld is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Oesterheld's full profile

Already have an account?

Office
1001 Blythe Blvd
Charlotte, NC 28203
Phone+1 704-381-9900

Fax+1 704-381-9901

Education & Training

New York Presbyterian Hospital (Cornell Campus)Fellowship, Pediatric Hematology/Oncology, 2004 - 2007
Rutgers New Jersey Medical SchoolResidency, Pediatrics, 2001 - 2004
Universidad Central del Caribe School of MedicineClass of 2001

Certifications & Licensure

NC State Medical License 2007 - 2025
ND State Medical License 2011 - 2012
NY State Medical License 2004 - 2007
NJ State Medical License 2002 - 2006
American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

Physician Practice Connections Recognition Program National Committee for Quality Assurance, 2011-2014

Clinical Trials

Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma Start of enrollment: 2008 Jan 14
Completed
Phase 2
T-cell Depleted Alternative Donor Transplantation Start of enrollment: 2009 Aug 01
Terminated
Phase 2
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL Start of enrollment: 2010 Jun 01
Terminated
Phase 1, Phase 2
Donor Lymphocyte Infusion After Alternative Donor Transplantation Start of enrollment: 2009 Aug 01
Terminated
Phase 1, Phase 2
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies Start of enrollment: 2011 Mar 01
Completed
Phase 1
AC220 for Children With Relapsed/Refractory ALL or AML Start of enrollment: 2011 Sep 01
Completed
Phase 1
A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL Start of enrollment: 2011 Dec 01
Terminated
Phase 1, Phase 2
Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma Start of enrollment: 2011 Dec 01
Terminated
Phase 1, Phase 2
Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma Start of enrollment: 2011 Dec 01
Terminated
Phase 1, Phase 2
Preventative Trial of DFMO in Patients With High Risk Neuroblastoma in Remission Start of enrollment: 2012 Jun 01
Active, not recruiting
Phase 2
Molecular-Guided Therapy for Relapsed and Refractory Childhood Cancer Start of enrollment: 2013 Mar 04
Completed
Not Applicable
Molecular-Guided Therapy for Childhood Cancer Start of enrollment: 2014 Jul 08
Completed
Not Applicable
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy Start of enrollment: 2015 Sep 01
Recruiting
Phase 2
Trial of Tolcapone With Oxaliplatin for Neuroblastoma Start of enrollment: 2015 Dec 01
Terminated
Phase 1
A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma Start of enrollment: 2016 Mar 01
Completed
Phase 1, Phase 2
Neuroblastoma Maintenance Therapy Trial Start of enrollment: 2016 Feb 01
Recruiting
Phase 2
Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma Start of enrollment: 2016 Oct 25
Active, not recruiting
Phase 2
PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy Start of enrollment: 2021 Sep 20
Recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

Phase II Trial of Gemcitabine and Nab-Paclitaxel for Recurrent Osteosarcoma with Serial Monitoring Using Liquid Biopsy: A Report from the National Pediatric Cancer Fou...
Aditi Dhir, Masanori Hayashi, Avery Bodlak, Javier Oesterheld, David M Loeb
Clinical Cancer Research. 2024-12-02
Panobinostat Synergizes with Chemotherapeutic Agents and Improves Efficacy of Standard-of-Care Chemotherapy Combinations in Ewing Sarcoma Cells.
Kaitlyn H Smith, Erin M Trovillion, Chloe Sholler, Divya Gandra, Kimberly Q McKinney
Cancers. 2024-10-23
3 citations
Molecular-guided therapy for the treatment of patients with relapsed and refractory childhood cancers: a Beat Childhood Cancer Research Consortium trial.
Giselle L Saulnier Sholler, Genevieve Bergendahl, Elizabeth C Lewis, Jacqueline Kraveka, William Ferguson
Genome Medicine. 2024-02-12

Journal Articles

Pediatric ALK+ anaplastic large cell lymphoma with t(3:8)(q26.2;q24) translocation and c-myc rearrangement terminating in a leukemic phase.
Sara Monaco, Lawrence Tsao, Vundavalli VS Murty, Subhadra V Nandula, Virginia Donovan, Javier E Oesterheld, Govind Bhagat, and Bachir Alobeid, American Journal of Hematology, 9/5/2006

Other

Investigation of mean platelet volume as a predictor of acute versus chronic immune thrombocytopenic purpura in children: An exploratory analysis
Jessica Keim-Malpass, Jenifer L. Lavigne, Jennifer Pope, Javier Oesterheld, Clinical Nursing Studies Vol. 3, No.3
2015
More Clinical Research Sites Needed for Pediatric Oncology
Javier E Oesterheld, Oncology Times
8/26/2010
Myeloablative chemotherapy with autologous stem cell rescue for Ewing sarcoma
Gilman AL, Oesterheld J, Bone Marrow Transplant 42 (11)
2008

Press Mentions

Atrium Health Levine Children’s Hospital Launches ARISE Cancer ConsortiumOctober 23rd, 2024
Shop TalkOctober 5th, 2020
Integrated Teamwork Ensures That Pediatric Cancer Patients Receive Medication, Despite National Drug ShortageJanuary 24th, 2020
Join now to see all